Member Info for B2HS2L

I think a decent offer for FUM would mean you would make many times your 62p average sp MB65. I'm not advocating a fire sale here, although the aftermath of feeling after the C&D disappointment might make it seem so. I also have waited 4 years for large Pharma to see what value can be added by using Dermasys to grab market share. I am waiting for the first decent offer, because I believe other offers will follow. No-one is going to want to allow their competitors to acquire the likes of Dermasys and MED2002 without a fight, the patents for these are worth many times the present sp. I hope I have made myself clearer.

The company is a steal at this price. ++++++++++++++++++++++++++++ I'd like a large pharmaceutical to make a decent bid for FUM, then we can all get on with our lives. The practices agreements and regulatory processes of making Pain Killers, Condoms, and the fastest acting ED medication commercially available is frustrating and taking way too long. JB must be planning a very late retirement.

The news only affects the distribution of CSD500 condoms. The situation has not changed with regard to Pain Relief or MED2002. MED2002 news is the subject that sends the market mad. Share price is now oversold IMO. If C&D were somehow responsible for Blue Diamond not in stock in Holland / Belgium, maybe the web site will be all stocked up overnight..

Further to my original post, I have looked at NHS and associated websites, and unfortunately it seems that ED is a well known symptom in men of Diabetes. On another subject, it is reported on iii FUM BB that Church and Dwight registered the trademark 'Amplify' in UK last Friday, and that 'Amplify' is being registered, or has been registered in other European countries. It is still unclear whether 'Amplify' is the name C&D have given to CSD500, but if so, then it is another piece in the jigsaw, and UK / Europe launch of CSD500 via C&D is a little nearer.

This could increase the number of MED2002 prescriptions significantly if the link is proven. http://www.huffingtonpost.co.uk/entry/erectile-dysfunction-causes-and-treatment_uk_596f2516e4b0a03aba8606e1?icid=maing-grid7%7Cmain5%7Cdl1%7Csec1_lnk2%26pLid%3D-1631655126_uk

I agree di, and there are already a number of ii's invested (@ 57p last year). I think these ii's will have already mentioned now they have invested, that they wish to see more action to minimise falling sp when there is no news. So this presentation will achieve that, and also; a) reminds investors of where we are, and just how many milestones have been achieved b) informs everyone that time scales have not slipped c) shop windows FUM's unique products available for distribution now or in the not too distant future d) creates a reference for all interested parties on the website. This share is in dire need of news though, - get with the program C&D

getting hit, MM's needing your shares? - News must be in the offing. sp needs to be a little lower to be a good buying opportunity.

I have criticised FUM BOD in the past for not doing anything to support the sp when it slips like this, and wasn't the only investor to say this. The video appears to be an attempt to do something to support the sp, but unfortunately it isn't the news we were expecting (on so many fronts). I contacted JB recently asking if two Phase 111 studies would double our costs. JB responded with the following quote: Quote begins The costs will be higher but this contingency was basically taken into account when we raised cash last October. By expanding the clinical programme it hopefully not only addresses any regulatory requirements but increases the likelihood of meeting our clinical endpoints and provides further reassurance for prospective commercial out-licensing partners. We believe any commercial deal will more than compensate the incremental rise in cost. End Quote. That could be interpreted that he intends to recoup the cost of one extra study in an improved commercial deal.

notrac: If you look at member Info for B2HS2L, - my posts dated 2 Nov 2016, - you will see I had similar concerns before the last General meeting, - concerning resolution content and perceived threat of dilution, - and had a response from Derek Martin allaying my fears. I'm not happy about the 'standard practice' bit, but every silver lining (FUM share ownership) has a cloud.

notrac: http://www.futuramedical.com/archive/2017-AGM-Notice.pdf on company website is a .pdf file. Page 2 - explanatory notes details 6 resolutions.

a)Before MED2002 and Painkillers are ready for market X because Dermasys is too attractive to large Pharma. b)around the time MED2002 and Painkillers are ready for market c)after MED2002 and Painkillers are available on the market d) FUM will not be of interest to large Pharma. e) Any other (stated) option

How many FUM investors think that offers for the company from large Pharma will occur : a)Before MED2002 and Painkillers are ready for market b)around the time MED2002 and Painkillers are ready for market c)after MED2002 and Painkillers are available on the market d) FUM will not be of interest to large Pharma. e) Any other (stated) option - This is for everyone using LSE invested in FUM , and tries to identify the most popular time scale. Just copy the five options and place your X against ONE option, and any text you want to add. If you turn out to be wrong but remain invested, you might end up even wealthier..

I would want to be invested to the hilt if/when offers start arriving for the company. I am sure if one offer arrives, many will follow. No major Pharma will want to see Dermasys sold to a major competitor without a fight, and I feel this is more and more likely to happen as pain killers and MED2002 move closer to market. Opinion: Buy and Hold

I don't know when the bidding will start, and that's why I must stay invested here day in day out. It could be an offer arrives Monday Morning, or March next year, - but sure as eggs are eggs, it won't be the only offer, - the prize is way too big to allow the competition to prevail without a fight. Each bidder will want to ensure that if their bid is not successful, then the successful bidder pays the highest price possible. The sp will never return to pre Sept 2016 levels, and the rights to DermaSys and MED2002 alone are each worth way more than current Market Capitalisation. News that a further MED2002 patent has been applied for, timing out in 2038 instead of 2025 / 2028, should be concentrating the minds of interested parties. If the patent application succeeds, the price of acquiring the rights to MED2002 will increase substantially overnight, better to make offers sooner rather than later. As for the timing of any offers, again big Pharma will not want to wait until MED2002 is approved and distributors lined up, as the cost will have escalated greatly by then. Again, better to make offers sooner rather than later, at a (much) lower acquisition cost.

CSD500 - "already had a repeat order from the middle east" - assume this to mean that Kabey is buying stock for another Middle east country launch, not that Saudi Arabia is fresh out. - love to be wrong though. F.lima - Marketing plans needed, else we are in the same situation as Holland / Belgium in a Catholic country. C&D agreement covers "North America and a number of key European territories", obviously not Portugal. If no distributor has taken Brazil yet, F.Lima might be suitable. Last page of yesterdays presentation: Vision and Objectives: Last Bullet Point - "Deliver Shareholder value". - shouldn't that be the first Bullet Point? - At least we know where we stand.

I think bidding will start before the most attractive products are ready for market, but that does not necessarily mean soon. A lot of effort will be expended by big pharma with deep pockets to acquire Dermasys and MED2002, not least because they would do anything rather than see them in another companies ownership. IE - Chelsea buying all the best players, so they are not available to the likes of Manchester United. Now that the IPSOS report has confirmed that MED2002 is a disruptive product, - game-changer is a more suitable word, - it will be harder for potential purchasers to rubbish FUM claims that the product and technology really are game-changes.

That would be my best case scenario, but no evidence it might happen soon. What price the full set of FUM product rights and licensing agreements if they were to become available? Certainly more than present Market Cap.

I would like to know if we can expect the income from sales of MED2002 as a prescription 'special' to be itemised in the accounts on 23 March, or will it be grouped with other income. I'm sure JB will not be specific if I ask a direct question, so does anyone have prior experience from other investments? What was the date it was made available to the medical profession please?

Agreed Bruce, FUM already has a patent for MED2002. So any time extension to that patent will likely push the price up for an acceptable offer.

For any large Pharma thinking of making an offer for FUM, the news that a patent extension (backed by IPR info) has been applied for will not be welcome. Any buyout plans will need to be reviewed as the price will rise if/when the extension is granted. The IPSOS review will have given MED2002 claims much more sales & marketing credence, and purchasers will now have to acknowledge this. The IPSOS review has confirmed MED 2002 is a disruptive product, with sales projections (accurate to within approx. 20%) to boot. For large Pharma, the opportunity to purchase FUM is now (or very shortly), before the price rises too high. The longer they leave it to make an offer, the more likely it is that an opportunity will be missed, and that MED2002, - and other world beating products - will exist in a competitors catalogue. James Barder, congratulations, the IPSOS report was money well spent.